Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 11 studies | 22% ± 7% | |
CD16-positive, CD56-dim natural killer cell, human | 5 studies | 27% ± 13% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 37% ± 14% | |
CD8-positive, alpha-beta T cell | 3 studies | 20% ± 3% |
Insufficient scRNA-seq data for expression of FASLG at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 96% | 85.85 | 554 / 578 | 69% | 2.57 | 800 / 1155 |
stomach | 73% | 22.70 | 261 / 359 | 52% | 1.86 | 148 / 286 |
kidney | 61% | 16.84 | 54 / 89 | 63% | 3.42 | 569 / 901 |
uterus | 59% | 11.49 | 100 / 170 | 62% | 3.19 | 283 / 459 |
thymus | 81% | 26.49 | 532 / 653 | 38% | 1.23 | 232 / 605 |
liver | 87% | 35.28 | 197 / 226 | 23% | 0.75 | 93 / 406 |
intestine | 55% | 24.95 | 533 / 966 | 50% | 1.47 | 265 / 527 |
breast | 45% | 8.65 | 206 / 459 | 60% | 2.34 | 670 / 1118 |
bladder | 62% | 18.62 | 13 / 21 | 41% | 1.38 | 206 / 504 |
lymph node | 0% | 0 | 0 / 0 | 100% | 20.11 | 29 / 29 |
spleen | 100% | 354.55 | 241 / 241 | 0% | 0 | 0 / 0 |
prostate | 70% | 19.16 | 172 / 245 | 23% | 0.45 | 113 / 502 |
esophagus | 45% | 8.98 | 653 / 1445 | 44% | 1.17 | 80 / 183 |
tonsil | 0% | 0 | 0 / 0 | 89% | 6.46 | 40 / 45 |
peripheral blood | 81% | 167.19 | 750 / 929 | 0% | 0 | 0 / 0 |
skin | 18% | 2.38 | 321 / 1809 | 62% | 4.14 | 291 / 472 |
pancreas | 24% | 3.44 | 79 / 328 | 39% | 0.92 | 69 / 178 |
adipose | 56% | 13.80 | 675 / 1204 | 0% | 0 | 0 / 0 |
ovary | 20% | 2.83 | 36 / 180 | 34% | 0.89 | 147 / 430 |
adrenal gland | 47% | 8.21 | 120 / 258 | 7% | 0.13 | 16 / 230 |
heart | 36% | 5.36 | 312 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 35% | 7.68 | 465 / 1335 | 0% | 0 | 0 / 0 |
brain | 21% | 2.93 | 551 / 2642 | 4% | 0.10 | 27 / 705 |
eye | 0% | 0 | 0 / 0 | 16% | 0.90 | 13 / 80 |
muscle | 4% | 0.43 | 32 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0097191 | Biological process | extrinsic apoptotic signaling pathway |
GO_0097190 | Biological process | apoptotic signaling pathway |
GO_0006919 | Biological process | activation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0048388 | Biological process | endosomal lumen acidification |
GO_0007165 | Biological process | signal transduction |
GO_0008625 | Biological process | extrinsic apoptotic signaling pathway via death domain receptors |
GO_1903514 | Biological process | release of sequestered calcium ion into cytosol by endoplasmic reticulum |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0007267 | Biological process | cell-cell signaling |
GO_0070231 | Biological process | T cell apoptotic process |
GO_0043525 | Biological process | positive regulation of neuron apoptotic process |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_0045742 | Biological process | positive regulation of epidermal growth factor receptor signaling pathway |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0046666 | Biological process | retinal cell programmed cell death |
GO_0030644 | Biological process | intracellular chloride ion homeostasis |
GO_0097527 | Biological process | necroptotic signaling pathway |
GO_0006915 | Biological process | apoptotic process |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0006925 | Biological process | inflammatory cell apoptotic process |
GO_1905782 | Biological process | positive regulation of phosphatidylserine exposure on apoptotic cell surface |
GO_0070266 | Biological process | necroptotic process |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0070848 | Biological process | response to growth factor |
GO_2000353 | Biological process | positive regulation of endothelial cell apoptotic process |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0071346 | Biological process | cellular response to type II interferon |
GO_0005615 | Cellular component | extracellular space |
GO_0060205 | Cellular component | cytoplasmic vesicle lumen |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0070062 | Cellular component | extracellular exosome |
GO_0043202 | Cellular component | lysosomal lumen |
GO_0005901 | Cellular component | caveola |
GO_0005634 | Cellular component | nucleus |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005123 | Molecular function | death receptor binding |
GO_0005164 | Molecular function | tumor necrosis factor receptor binding |
GO_0005515 | Molecular function | protein binding |
GO_0005125 | Molecular function | cytokine activity |
Gene name | FASLG |
Protein name | Tumor necrosis factor ligand superfamily member 6 (Apoptosis antigen ligand) (APTL) (CD95 ligand) (CD95-L) (Fas antigen ligand) (Fas ligand) (FasL) (CD antigen CD178) [Cleaved into: Tumor necrosis factor ligand superfamily member 6, membrane form; Tumor necrosis factor ligand superfamily member 6, soluble form (Receptor-binding FasL ectodomain) (Soluble Fas ligand) (sFasL); ADAM10-processed FasL form (APL); FasL intracellular domain (FasL ICD) (SPPL2A-processed FasL form) (SPA)] Tumor necrosis factor ligand superfamily member 6 (CD95 ligand) (Fas antigen ligand) |
Synonyms | FASL CD95L hCG_37643 APT1LG1 TNFSF6 TNLG1A |
Description | FUNCTION: Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells . Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development . Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses (By similarity). TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance (By similarity). Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis . .; FUNCTION: [Tumor necrosis factor ligand superfamily member 6, soluble form]: Induces FAS-mediated activation of NF-kappa-B, initiating non-apoptotic signaling pathways (By similarity). Can induce apoptosis but does not appear to be essential for this process . .; FUNCTION: [FasL intracellular domain]: Cytoplasmic form induces gene transcription inhibition. . FUNCTION: Cytoplasmic form induces gene transcription inhibition. . FUNCTION: Cytoplasmic form induces gene transcription inhibition. . FUNCTION: Cytoplasmic form induces gene transcription inhibition. . |
Accessions | Q0VHD7 A0A0H3VB22 Q53ZZ1 P48023 ENST00000367721.3 [P48023-1] ENST00000340030.4 [P48023-2] |